Clinical Trials Browser

Approved for marketing × larotrectinib × Clear all

NCT03025360 2019-12-19

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Approved for marketing

Tumors Harboring NTRK Fusion